Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of pre-percutaneous coronary intervention ticagrelor administration on coronary reperfusion and short-term prognosis in patients with acute myocardial infarction
Abstract
Purpose: To investigate the effect of ticagrelor administration prior to percutaneous coronary intervention (PCI) on coronary reperfusion and short-term prognosis in patients with acute myocardial infarction.
Methods: A total of 200 patients treated for acute myocardial infarction in The Second Affiliated Hospital of Qiqihar Medical College between May 2021 and October 2022 were assigned to receive either clopidogrel (control group) or ticagrelor (Ticagrelor group) before PCI, in a 1:1 ratio, with 100 patients in each group. Clinical indices, serum C-reactive protein (CRP), inhibition of platelet aggregation (IPA), lipid indices, coronary reperfusion, and short-term prognosis of the patients were analyzed to investigate the effectiveness of the pre- intervention.
Results: Patients receiving ticagrelor exhibited significantly lower levels of maximum platelet aggregation rate (MAR), P2Y12 reaction units (PRU), and left ventricular end-diastolic diameter (LVDD) and higher left ventricular ejection fraction (LVEF) than those given clopidogrel (p < 0.01). Also. patients administered pre-interventional ticagrelor administration exhibited significantly lower serum concentrations of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) than those who received clopidogrel (p < 0.01), suggesting a better overall blood lipid profile for the former. Pre-PCI ticagrelor administration significantly mitigated inflammatory reactions more than clopidogrel, as evidenced by the reductions in serum CRP, cTnI, and CK-MB levels (p < 0.01). It further resulted in a lower risk of abnormal platelet aggregation than pre-interventional clopidogrel (p < 0.01).
Conclusion: Pre-interventional ticagrelor administration after the onset of acute myocardial infarction produces significant improvement in clinical indices and platelet indices, normalized blood lipid profiles, shortens coronary reperfusion, and enhances short-term prognosis of patients. Future randomized controlled trials with larger sample sizes and the use of more centers are required to validate the current results.
